@article{89d05d6cae444be8b3e20409282e72fd,
title = "Efficacy and Safety of palbociclib (PAL) in Patients (pts) with Estrogen Receptor-positive (ER+)/human Epidermal Growth Factor Receptor 2-negative (HER2-) Advanced Breast Cancer (ABC) with Preexisting Conditions: A Post Hoc Analysis of PALOMA-2",
abstract = " K. Gelmon; J. Walshe; A. Joy; M. Karturi; P. Neven; D. Lu; S. Kim; P. Schnell ",
author = "Reshma Mahtani",
note = "Abstract. Background: In the PALOMA-2 trial, PAL + letrozole (LET) significantly prolonged progression-free survival (PFS) vs placebo (PBO) + LET in pts with ER+/HER2- ABC. This post hoc analysis assessed efficacy and safety of PAL + LET in pts from PALOMA-2 with baseline preexisting conditions grouped by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC).",
year = "2021",
month = feb,
day = "15",
language = "American English",
volume = "81",
journal = "Cancer Research / San Antonio Breast Cancer Symposium",
}